Testing a new shot for HPV-related cervical pre-cancer
Part of Infections clinical trials.
This trial tests an experimental shot, BBM-C101, for women with a specific type of cervical pre-cancer caused by HPV types 16 or 18. The goal is to see if the shot is safe and can help the body fight the infection, possibly eliminating the abnormal cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a cervical biopsy showing high-grade pre-cancer (HSIL) linked to HPV type 16 or 18.
- Your colposcopy (a special magnified exam of the cervix) must be clear enough to see the area, and a sample from inside the cervical canal must not show cancer
- You cannot be pregnant or nursing, and if you could become pregnant, you must use effective birth control for a year after the shot
- You must not have had previous treatment for HPV or this cervical condition, or any prior HPV vaccine except the standard preventive ones.
- You cannot have certain other infections, autoimmune diseases, or unstable heart or blood vessel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NWRD09 for women with a high-grade precancerous cervical condition caused by HPV type 16. If you qualify, you would receive the study drug and be monitored to see if it can help clear the abnormal cells.
This study tests a new treatment (NWRD08) for women with high-grade cervical changes (CIN 2/3) caused by HPV types 16 or 18. It aims to see if the treatment can help clear the abnormal cells and prevent them from becoming cancer.
This trial tests a new drug called BL-B01D1, alone or combined with another drug (SI-B003), for people with cervical or other gynecologic cancers that have spread or come back after standard treatments. The goal is to see if this treatment can help when other options have stopped working.
This trial tests a new drug called NWRD09 for women with high-grade cervical cell changes (CIN 2/3) caused by HPV type 16. The goal is to see if the drug can help clear these abnormal cells without needing surgery.
This trial tests a new injection called BBM-C101 for people with a long-lasting HPV16 or HPV18 infection that hasn't gone away with other treatments, or who choose not to have surgery. The goal is to see if the vaccine can help the body clear the virus and prevent precancerous changes from getting worse.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
Hear when a new High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.